Quinupristin + Dalfopristin information from DrugsUpdate
Quinupristin + Dalfopristin are indicated for the treatment of complicated skin and skin structure infection caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.
Pharmacodynamics
Quinupristin + Dalfopristin inhibit the bacterial ribosome in the susceptible micro organisms. Dalfopristin and Quinupristin inhibit early phase of protein synthesis and late phase of protein synthesis, respectively. Quinupristin + Dalfopristin exerts bactericidal property against methicillin-resistant and methicillin-susceptible staphylococci.
Pharmacokinetics
No information available
Quinupristin + Dalfopristin Indications / Quinupristin + Dalfopristin Uses
No information available
Quinupristin + Dalfopristin Adverse Reactions / Quinupristin + Dalfopristin Side Effects
Quinupristin + Dalfopristin may phlebitis, abdominal pain, allergic reactions, fever, infections, gout, peripheral edema, myasthenia, arthralgia, urticaria, constipation, sweating, GI upset, constipation, pleural effusion, dyspnoea, sweating, urticaria, vaginitis, hematuria, injection-site reactions, pain, rashes and pruritus.
Precautions
Caution should be exercised while administering Quinupristin + Dalfopristin to avoid thrombophlebitis, myalgia, arthralgia, super-infections and hyperbilirubinemia.
Special Precautions
No information available
Other Drug Interactions
Quinupristin + Dalfopristin may interact with digoxin, cytochrome P4503A4 inhibitors, gentamicin, amoxicillin, tetracyclines, quinolones, beta-lactams, anti-histaminic drugs, benzodiazepines, HMG-CoA reductase inhibitors, calcium-channel blockers, anti-neoplastic drugs, protease inhibitors, benzodiazepines and Clostridium difficile associated diarrhea (CDAD)
Other Interactions
No information available
Dosage
Quinupristin + Dalfopristin should be administered as an intravenous infusion in 5% dextrose in water over one hour. The recommended dose of Quinupristin + Dalfopristin is 7.5 mg/kg, q12 h for seven days.
Food(before/after)
No information available
List of Contraindications
Quinupristin + Dalfopristin and Pregnancy
USFDA pregnancy category B. Quinupristin + Dalfopristin may not cause harm to an unborn foetus. Before Quinupristin + Dalfopristin treatment, the patient should discuss with the physician, if they are planning for a pregnancy.
Quinupristin + Dalfopristin and Lactation
It is unclear whether the drug could pass through the breast milk to a breast feeding baby. Consult your physician before taking Quinupristin + Dalfopristin, if you are nursing mother.
Quinupristin + Dalfopristin and Children
Quinupristin + Dalfopristin should not be given to children younger than 16 years of age.
Quinupristin + Dalfopristin and Geriatic
No information available
Quinupristin + Dalfopristin and Other Contraindications
No information available
Storage
No information available
Lab interference
No information available
FOLLOW US:
